Publication | Open Access

Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer

Surgical OncologyRadiation MedicinePancreatic CancerRadiation TherapyMedicineNeoadjuvant FolfirinoxFixed-dose Rate-gemcitabineSurgeryPhase 2OncologyRadiation OncologyCancer Research